

Alexa Fluor[®] 700 anti-mouse CD19 Antibody

Catalog# / Size	115527 / 25 µg 115528 / 100 µg
Clone	6D5
Regulatory Status	RUO
Other Names	B4
Isotype	Rat IgG2a, κ
Description	CD19 is a 95 kD glycoprotein also known as B4. It is a member of the Ig superfamily, expressed on all pro-B to mature B cells (during development) and follicular dendritic cells. Plasma cells do not express CD19. CD19, in association with CD21 and CD81, forms a molecular complex integral to B cell activation.

Product Details

Verified Reactivity	Mouse
Antibody Type	Monoclonal
Host Species	Rat
Immunogen	Mouse CD19-expressing K562 human erythroleukemia cells
Formulation	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation	The antibody was purified by affinity chromatography and conjugated with Alexa Fluor [®] 700 under optimal conditions.
Concentration	0.5 mg/ml
Storage & Handling	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application	FC - Quality tested
Recommended Usage	<p>Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. The suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is highly recommended that the reagent be titrated for optimal performance for each application.</p> <p>* Alexa Fluor[®] 700 has a maximum emission of 719 nm when it is excited at 633 nm / 635 nm. Prior to using Alexa Fluor[®] 700 conjugate for flow cytometric analysis, please verify your flow cytometer's capability of exciting and detecting the fluorochrome.</p> <p>Alexa Fluor[®] and Pacific Blue™ are trademarks of Life Technologies Corporation.</p> <p>View full statement regarding label licenses</p>
Excitation Laser	Red Laser (633 nm)
Application Notes	Additional reported applications (for the relevant formats) include: immunofluorescence ⁷ .
Application References	<ol style="list-style-type: none">1. Shoham T, <i>et al.</i> 2003. <i>J. Immunol.</i> 171:4062. (FC)2. Goodyear CS, <i>et al.</i> 2004. <i>J. Immunol.</i> 172:2870. (FC)3. Kamimura D, <i>et al.</i> 2006. <i>J. Immunol.</i> 177:306. (FC)4. Andoniou CE, <i>et al.</i> 2005. <i>Nat. Immunol.</i> 6:1011. (FC)5. Lawson BR, <i>et al.</i> 2007. <i>J. Immunol.</i> 178:5366. (FC)6. Phan TG, <i>et al.</i> 2007. <i>Nat. Immunol.</i> 8:992. (FC)7. Hayashida K, <i>et al.</i> 2008. <i>J. Biol. Chem.</i> 283:19895. (IF) PubMed8. Charles N, <i>et al.</i> 2010. <i>Nat. Med.</i> 16:701. (FC) PubMed9. Bankoti J, <i>et al.</i> 2010. <i>Toxicol. Sci.</i> 115:422. (FC) PubMed10. Stadnisky MD, <i>et al.</i> 2011. <i>Blood.</i> 117:5133. (FC) PubMed11. Perlot T, <i>et al.</i> 2012. <i>J. Immunol.</i> 188:1201. (FC) PubMed
(PubMed link indicates BioLegend citation)	

12. Olive V, *et al.* 2013. *Elife*. 2:822. [PubMed](#)
13. Miyai T, *et al.* 2014. *PNAS*. 111:11780. [PubMed](#)

Product Citations

1. Apte SH, *et al.* 2020. *Clin Transl Immunology*. 9:e1209. [PubMed](#)
2. Kwong Chung CK, *et al.* 2017. *Immunology*. 150:221. [PubMed](#)
3. Harsha Krovi S, *et al.* 2020. *Nat Commun*. 4.790277778. [PubMed](#)
4. Kitagawa S, *et al.* 2022. *NPJ Vaccines*. 7:115. [PubMed](#)
5. Li J, *et al.* 2010. *J Immunol*. 184:6142. [PubMed](#)
6. Groza D, *et al.* 2018. *Oncoimmunology*. 7:e1424676. [PubMed](#)
7. Kaczanowska S, *et al.* 2021. *Cell*. 184(8):2033-2052.e21. [PubMed](#)
8. Boldison J, *et al.* 2020. *Cell Mol Immunol*. 17:843. [PubMed](#)
9. Lino AC *et al.* 2018. *Immunity*. 49(1):120-133. [PubMed](#)
10. Andreas N, *et al.* 2021. *Arthritis Res Ther*. 23:222. [PubMed](#)
11. Periasamy S, *et al.* 2017. *Nat Commun*. 8:15564. [PubMed](#)
12. Chow MT *et al.* 2019. *Immunity*. 50(6):1498-1512. [PubMed](#)
13. Pack AD, *et al.* 2021. *Cell Reports*. 36(8):109586. [PubMed](#)
14. Hreha TN, *et al.* 2020. *Front Immunol*. 11:597916667. [PubMed](#)
15. Go DM, *et al.* 2021. *Cell Mol Gastroenterol Hepatol*. 12:715. [PubMed](#)
16. Perry D, *et al.* 2012. *J Immunol*. 189:793. [PubMed](#)
17. Mathew NR, *et al.* 2021. *Cell Reports*. 35(12):109286. [PubMed](#)
18. Sarapulov AV, *et al.* 2020. *Front Immunol*. 11:599. [PubMed](#)
19. Roy R, *et al.* 2022. *Elife*. 11:. [PubMed](#)
20. Kenderes KJ, *et al.* 2018. *Cell Rep*. 24:824. [PubMed](#)
21. Wong R, *et al.* 2020. *Immunity*. 53(5):1078-1094.e7. [PubMed](#)
22. Yewdell WT, *et al.* 2020. *Immunity*. 53(5):952-970.e11. [PubMed](#)
23. Aldrich AL, *et al.* 2021. *The Journal of Immunology*. 206(4):751-765. [PubMed](#)
24. Doonan J, *et al.* 2019. *Nat Commun*. 10:1554. [PubMed](#)
25. Doron I, *et al.* 2021. *Cell*. 184(4):1017-1031.e14. [PubMed](#)
26. Harnett MM, *et al.* 2022. *Front Immunol*. 13:953053. [PubMed](#)
27. Vogel AB, *et al.* 2021. *Nature*. 592:283. [PubMed](#)
28. Li H, *et al.* 2020. *Nature*. 584:274. [PubMed](#)
29. Wu S, *et al.* 2022. *BMC Immunol*. 23:17. [PubMed](#)
30. Oguri Y, *et al.* 2020. *Cell*. 182(3):563-577.e20. [PubMed](#)
31. Giampazolias E, *et al.* 2021. *Cell*. [PubMed](#)
32. Matsuda T, *et al.* 2022. *iScience*. 25:105324. [PubMed](#)
33. Kalafati L, *et al.* 2020. *Cell*. 183:771. [PubMed](#)
34. Chitu V, *et al.* 2020. *Cell Reports*. 30(9):3004-3019. [PubMed](#)
35. Holm J, *et al.* 2015. *PLoS One*. 10:125495. [PubMed](#)
36. Vijay R, *et al.* 2021. *J Exp Med*. 218:. [PubMed](#)
37. Miyauchi K, *et al.* 2021. *Nat Commun*. 12:3789. [PubMed](#)
38. Bennion BG, *et al.* 2019. *J Virol*. 93. [PubMed](#)
39. Damgaard RB *et al.* 2016. *Cell*. 166(5):1215-1230. [PubMed](#)
40. Rinaldi S, *et al.* 2021. *PLoS Pathog*. 17:e1009533. [PubMed](#)
41. Seenappa LM, *et al.* 2022. *NPJ Vaccines*. 7:128. [PubMed](#)
42. Vijay R, *et al.* 2020. *Nat Immunol*. 21:790. [PubMed](#)
43. Platteel ACM, *et al.* 2018. *Front Immunol*. 9:1544444444. [PubMed](#)
44. Cruz F, *et al.* 2016. *Stem Cells Trans Med*. 5: 488-499. [PubMed](#)
45. Gorman M, *et al.* 2016. *J Virol*. 90: 8212 - 8225. [PubMed](#)
46. Goldberg EL, *et al.* 2021. *Cell Metabolism*. [PubMed](#)

RRID

AB_493734 (BioLegend Cat. No. 115527)
 AB_493735 (BioLegend Cat. No. 115528)

Antigen Details

Structure	Ig superfamily, associates with CD21 and CD81, 95 kD
Distribution	Pro-B cells to mature B cells (during development), follicular dendritic cells
Function	Modulates B cell activation and differentiation
Ligand/Receptor	CD21, CD81, Leu-13
Cell Type	B cells, Dendritic cells
Biology Area	Costimulatory Molecules, Immunology
Molecular Family	CD Molecules
Antigen References	<ol style="list-style-type: none"> 1. Fearon DT. 1993. <i>Curr. Opin. Immunol</i>. 5:341. 2. Krop I, <i>et al.</i> 1996. <i>Eur. J. Immunol</i>. 26:238. 3. Krop I, <i>et al.</i> 1996. <i>J. Immunol</i>. 157:48. 4. Tedder TF, <i>et al.</i> 1994. <i>Immunol. Today</i> 15:437.
Gene ID	12478


Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)

Other Formats

APC anti-mouse CD19, Biotin anti-mouse CD19, FITC anti-mouse CD19, PE anti-mouse CD19, PE/Cyanine5 anti-mouse CD19, Purified anti-mouse CD19, PE/Cyanine7 anti-mouse CD19, Alexa Fluor® 488 anti-mouse CD19, Alexa Fluor® 647 anti-mouse CD19, Pacific Blue™ anti-mouse CD19, Alexa Fluor® 700 anti-mouse CD19, APC/Cyanine7 anti-mouse CD19, PerCP anti-mouse CD19, PerCP/Cyanine5.5 anti-mouse CD19, Alexa Fluor® 594 anti-mouse CD19, Brilliant Violet 421™ anti-mouse CD19, Brilliant Violet 570™ anti-mouse CD19, Brilliant Violet 605™ anti-mouse CD19, Brilliant Violet 650™ anti-mouse CD19, Brilliant Violet 785™ anti-mouse CD19, Brilliant Violet 510™ anti-mouse CD19, Purified anti-mouse CD19 (Maxpar® Ready), PE/Dazzle™ 594 anti-mouse CD19, Brilliant Violet 711™ anti-mouse CD19, APC/Fire™ 750 anti-mouse CD19, TotalSeq™-A0093 anti-mouse CD19, Brilliant Violet 750™ anti-mouse CD19, TotalSeq™-B0093 anti-mouse CD19, Spark Blue™ 550 anti-mouse CD19, Spark NIR™ 685 anti-mouse CD19, TotalSeq™-C0093 anti-mouse CD19, Ultra-LEAF™ Purified anti-mouse CD19, PE/Fire™ 640 anti-mouse CD19 Antibody, Spark YG™ 581 anti-mouse CD19, APC/Fire™ 810 anti-mouse CD19, Spark YG™ 570 anti-mouse CD19, Spark Blue™ 574 anti-mouse CD19 Antibody

Product Data



C57BL/6 mouse splenocytes were stained with CD19 (clone 6D5) Alexa Fluor® 700 (filled histogram) or rat IgG2a, κ Alexa Fluor® 700 isotype control (open histogram).

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587